Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
基本信息
- 批准号:10684097
- 负责人:
- 金额:$ 28.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAdherenceAdverse eventAffectAnimal ModelAnti-Inflammatory AgentsAntioxidantsAortaArteriesAutosomal Dominant Polycystic KidneyBlood VesselsCardiovascular DiseasesCardiovascular systemCause of DeathChronic Kidney FailureClinicalClinical TrialsCystCystic Kidney DiseasesCystic kidneyDataDevelopmentDiabetes MellitusDiseaseDisease ProgressionDisease modelDiuresisDoseElasticityEnd stage renal failureEpithelial Cell ProliferationEpithelial cystEtiologyEventExclusionFeasibility StudiesFibrosisFrequenciesFunctional disorderGenetic DiseasesGenitourinary System InfectionGlomerular Filtration RateGlucoseGoalsGrowthGrowth and Development functionHealthHereditary DiseaseIndividualInjuryInterventionIntervention StudiesInvestigationKidneyKidney DiseasesLifeLiquid substanceMacula densaMagnetic Resonance ImagingMeasurementMeasuresModelingMorbidity - disease rateNatriuresisOsmosisOutcomeOxygenParticipantPatientsPharmaceutical PreparationsPhasePhase III Clinical TrialsPhysiologic pulsePlacebosPlasmaQuality of lifeRandomizedRattusRenal functionResearchRodentSafetySample SizeSodiumSpecific qualifier valueSymptomsTestingTubular formationUrinary tractVasopressin ReceptorVasopressinsantagonistarterial stiffnessconstrictioncostdiabeticdisorder riskdouble-blind placebo controlled trialefficacy clinical trialexperiencehealth related quality of lifehigh riskimprovedinhibitorinsightinterestloss of functionmortalitynon-diabeticpressureprogression riskrandomized trialrandomized, clinical trialsrat KIM-1 proteinreceptor expressionsafety assessmentsafety testingside effectstandard of caresuccesssymportertolvaptanurinary
项目摘要
PROJECT SUMMARY
Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that leads to end-
stage kidney disease. Despite decades of research, tolvaptan is the only approved intervention in ADPKD.
However, tolvaptan does not target cardiovascular complications of ADPKD and is constrained by high cost
and side effects that limit adherence. Therefore, there is an urgent need for a well-tolerated alternative
intervention to slow ADPKD progression and improve vascular health. Sodium-glucose cotransporters-2
inhibitors (SGLT2i) have a track record of tolerability and safety in patients with proteinuric diabetic and non-
diabetic kidney disease. Trials of SGLT2i in these conditions have been extremely encouraging, and these
treatments are highly likely to become the standard of care for diabetic and non-diabetic kidney disease;
however, the mechanisms of action are not fully elucidated, and may be non-specific to disease etiology. The
potential benefit of SGLT2i has not been examined in patients with ADPKD, as major trials have excluded such
patients. There are also potential benefits of SGLT2i to ADPKD patients beyond slowing loss of kidney
function, as this class of drugs provide a cardiovascular mortality benefit for patients across the CKD spectrum.
Studies testing the effects of SGLT2i in animal models of PKD have yield conflicting results. Five weeks of
treatment with an SGLT1 and SLGT2 inhibitor phlorizon was shown to inhibit cystogenesis in the Han:SPRD
rat model of PKD. The mechanisms by which SGLT2i slows cystic renal disease progression may be related to
inhibition of cyst epithelial cell proliferation. SGLT2i have also antioxidant and anti-inflammatory actions, which
are important for reducing fibrosis and improving vascular health, both of which occur in early stages of
ADPKD. While many changes likely contribute to the development of arterial dysfunction in patients with
ADPKD, among those of greatest concern is the development of stiffening of large elastic arteries, typically
assessed by aortic pulse wave velocity (aPWV). We propose a pilot randomized clinical trial to determine the
safety and tolerability of empagliflozin in ADPKD patients. To achieve this, we will conduct a 12-month parallel-
group, randomized, double-blind, placebo-controlled trial in 50 ADPKD patients with an eGFR 30-90
mL/min/1.73m2. Secondary, exploratory endpoints will determine the effect of empagliflozin on kidney volume,
kidney function, aPWV, plasma copeptin levels, urinary kidney injury molecule-1 (KIM-1) and quality of life.
Specific Aim 1: To determine the feasibility, in terms of safety and tolerability, of prescribing empagliflozin 25
mg once a day in ADPKD patients at risk for progression with an eGFR of 30-90 mL/min/1.73m2.
Specific Aim 2: To derive preliminary estimates of the effect of empagliflozin compared to placebo on 12-
month change in a) total kidney volume by magnetic resonance imaging, b) eGFR, c) plasma copeptin levels
(a marker of vasopressin secretion), d) urinary KIM-1 (a marker of tubular injury), e) aPWV; and f) ADPKD-
specific health-related quality of life (HRQoL) as quantified by the ADPKD-Impact Scale.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michel Benjamin Chonchol其他文献
Michel Benjamin Chonchol的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michel Benjamin Chonchol', 18)}}的其他基金
Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
- 批准号:
10464393 - 财政年份:2022
- 资助金额:
$ 28.82万 - 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
- 批准号:
10534531 - 财政年份:2022
- 资助金额:
$ 28.82万 - 项目类别:
Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
- 批准号:
10626828 - 财政年份:2022
- 资助金额:
$ 28.82万 - 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
- 批准号:
10669712 - 财政年份:2021
- 资助金额:
$ 28.82万 - 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
- 批准号:
10313126 - 财政年份:2021
- 资助金额:
$ 28.82万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
10640074 - 财政年份:2019
- 资助金额:
$ 28.82万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
10400032 - 财政年份:2019
- 资助金额:
$ 28.82万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
9762288 - 财政年份:2019
- 资助金额:
$ 28.82万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 28.82万 - 项目类别:
Fellowship Programs














{{item.name}}会员




